Jazz Pharmaceuticals

JAZZ Large Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$186.95

-0.7% today

52W: $95.49 – $198.00

52W Low: $95.49 Position: 89.2% 52W High: $198.00

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

7.49x

Forward Price/Earnings

P/S Ratio

2.7x

Price-to-Sales

EV/EBITDA

8.45x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$11.5B

Market Capitalization

Revenue Growth

10.1%

YoY Revenue Growth

Profit Margin

-8.35%

Net profit margin

ROE

-8.47%

Return on Equity

Beta

0.23

Market sensitivity

Short Interest

11.55%

% of float sold short

Avg. Volume

1,018,516

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

16 analysts

Avg. Price Target

$223.50

+19.55% upside

Target Range

$188.00 – $275.00

About the Company

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harb

Sector: Healthcare Industry: Biotechnology Country: Ireland Employees: 2,890 Exchange: NMS